Marina Biotech announced that it has appointed Daniel Geffken as its interim CFO as it works to restart drug-development operations after halting operations in mid-2012 amid a cash shortfall. Geffken is managing director at Danforth Advisors.

Marina has also brought back former executives Alan Dunton as chief medical officer and June Ameen as senior vice president of program management and strategic alliances. Both will work for Marina on a consulting basis, helping it to restart development of its suspended Phase I familial adenomatous polyposis program.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.